
Treatment of Cytomegalovirus (CMV) Retinitis: Valcyte is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).
Prevention of CMV Disease: Valcyte is indicated for the prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).
Prevention of CMV Disease: Valcyte is indicated for the prevention of CMV disease in kidney transplant patients (4 months to 16 years of age) and heart transplant patients (1 month to 16 years of age) at high risk.
from FDA,2021.12
LuciusVersionofVALCYTE:DosageandAdministration,Indications,PrecautionsIndicationsAdult Patients① Tre···【more】
Recommended:522025-15-12
Valcyte treatment for cytomegalovirus infection.【more】
Article source:Lucius LaosRelease date:2026-01-05Recommended:10
LuciusVersionofVALCYTE:DosageandAdministration,Indications,PrecautionsIndicationsAdult Patients① Treatment of CMV Retinitis in patients with AIDS;② Prevention of cytomegalovirus di···【more】
Article source:Lucius LaosRelease date:2025-12-15Recommended:52

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: